肺癌是最常见、发病率最高的恶性肿瘤之一。小细胞肺癌 (SCLC) 中基因突变很少见，因此靶向治疗仅是三线建议。 Surufatinib (Sulanda) 是一种口服血管免疫激酶抑制剂，用于治疗实体瘤。我们科室报道一例索凡替尼联合卡瑞利珠单抗治疗SCLC的病例，取得了良好的治疗效果。患者经历了超过 18 个月的无进展生存期和超过 28 个月的总生存期。这表明索凡替尼联合卡瑞利珠单抗是 SCLC 患者有效的三线治疗方法。然而，所有 SCLC 患者对索凡替尼治疗的反应率仍然未知，需要在大量人群中确定。版权所有 © 2023 Wolters Kluwer Health, Inc. 保留所有权利。

Lung cancer is one of the most common malignant tumors with the highest incidence. Gene mutations are rare in small-cell lung carcinoma (SCLC), resulting in targeted therapy being only a third-line recommendation. Surufatinib (Sulanda) is an oral angio-immune kinase inhibitor used to treat solid tumors. We report a case of SCLC treated with surufatinib combined with camrelizumab, with good therapeutic results in our department. The patient experienced over 18 months of progression-free survival and over 28 months of overall survival. This suggests that surufatinib combined with camrelizumab is an effective third-line treatment for SCLC patients. However, the response rate to surufatinib treatment in all patients with SCLC remains unknown and needs to be determined in a large population.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.